Table 1 Clinical characteristics of the study population
From: Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin
|  | PHI | LP-AD <200 cells/μL | LP-nonAD 200–350 cells/μL | EP >350 cells/μL | HC |
|---|---|---|---|---|---|
N = 14 | N = 20 | N = 24 | N = 42 | N = 18 | |
Gender, males/females, (% males) | 13/1 (92.9) | 18/2 (90.0) | 21/3 (87.5) | 39/3 (92.9) | 17/1 (94.4) |
Age, years, median (IQR) | 47 (12) | 42 (16) | 38 (16) | 44.5 (12) | 42.5 (12) |
Time since diagnosis, days, median (IQR) | 2 (3) | 3 (9) | 18 (269) | 24 (983) | NA |
CD4+ nadir, cells/μL, median (IQR) | 540 (335) | 45 (113) | 290 (95) | 480 (170) | NA |
CD4+ at baseline, cells/μL, median (IQR) | 550 (327) | 55 (110) | 290 (97) | 510 (172) | 983 (540) |
CD4/CD8 at baseline, median (IQR) | 0.5 (0.3) | 0.1 (0.1) | 0.3 (0.1) | 0.5 (0.3) | 1.5 (0.9) |
Co-infection with chronic HBV/HCV, N | 0/1 | 0/2 | 0/0 | 1/1 | 0/0 |
HIV-RNA at baseline, median (IQR) | 151,775 (3,442,296) | 196,589 (751,023) | 65,990 (89,637) | 49,422 (47,031) | NA |
AIDS defining events, N | 0 | 1 | 0 | 0 | NA |
Fiebig Stage I, N | 1 | NA | NA | NA | NA |
Fiebig Stage II, N | 1 | NA | NA | NA | NA |
Fiebig Stage III, N | 1 | NA | NA | NA | NA |
Fiebig Stage IV, N | 11 | NA | NA | NA | NA |